Evidence map›Paper›PMID 31865227›Full record

ArticleBiomaterials2020

Rilpivirine-associated aggregation-induced emission enables cell-based nanoparticle tracking.

Insiya Z Mukadam, Jatin Machhi, Jonathan Herskovitz, Mahmudul Hasan, Maxim D Oleynikov, Wilson R Blomberg, Denis Svechkarev, Aaron M Mohs, You Zhou, Prasanta Dash and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Pharmacotherapeutics of SARS-CoV-2 Infections.Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology · 2021
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Insiya Z MukadamDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.
Jatin MachhiDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.
Jonathan HerskovitzDepartment of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.
Mahmudul HasanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.
Maxim D OleynikovDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.
Wilson R BlombergDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.
Denis SvechkarevDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.
Aaron M MohsDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.
You ZhouCenter for Biotechnology, University of Nebraska-Lincoln, Lincoln, NE, USA.
Prasanta DashDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.
JoEllyn McMillanDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.
Santhi GorantlaDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.
Jered GarrisonDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA.
Howard E GendelmanDepartment of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, NE, 68198, USA; Department of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA; Department of Pathology and Microbiology, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA. Electronic address: hegendel@unmc.edu.
Bhavesh D KevadiyaDepartment of Pharmacology and Experimental Neuroscience, College of Medicine, University of Nebraska Medical Center, NE, 68198, USA.

Funding

UNMC Structural Biology CoreP20GM103427 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI PAUL L SORGEN · 2012 to 2026
$59.2M
UNMC/EPPLEY CANCER CENTER SUPPORT GRANTP30CA036727 · NCI · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Joann B. Sweasy · 1985 to 2026
$55.0M
Therapeutics Core (Page 286)P30MH062261 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BUCH, SHILPA J., FOX, HOWARD S · 2000 to 2021
$37.7M
Pharmacokinetics and Drug-Drug InteractionsP01DA028555 · NIDA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI BOSKA, MICHAEL DOUGLAS · 2010 to 2019
$16.8M
Neuroprotective Immunity and HIV DementiaR01NS034239 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Howard E Gendelman, R Lee Mosley · 1995 to 2026
$12.3M
Nanomedicine and NeuroAIDSR01NS036126 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 1997 to 2017
$5.7M
Research Pilot Project ProgramP30GM106397 · NIGMS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI JOHNSON, KEITH R · 2013 to 2017
$4.9M
Combined Molecular Excision Therapy (CMET) for Eliminating HIV-1R01MH115860 · NIMH · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E · 2017 to 2021
$3.5M
SMART HANDR01AG043540 · NIA · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI GENDELMAN, HOWARD E, POLUEKTOVA, LARISA Y · 2013 to 2017
$3.1M
Neuroimmunology of Disease Training ProgramT32NS105594 · NINDS · UNIVERSITY OF NEBRASKA MEDICAL CENTER · PI Aditya N Bade, Howard E Gendelman · 2018 to 2026
$1.4M
NCI NIH HHS P30 CA036727NIA NIH HHS R01 AG043540NIDA NIH HHS P01 DA028555NIGMS NIH HHS P20 GM103427NIGMS NIH HHS P30 GM106397NIMH NIH HHS P30 MH062261NIMH NIH HHS R01 MH115860NINDS NIH HHS R01 NS034239NINDS NIH HHS R01 NS036126NINDS NIH HHS T32 NS105594
6 · The paper itself

Abstract

Antiretroviral therapy (ART) has improved the quality and duration of life for people living with human immunodeficiency virus (HIV) infection. However, limitations in drug efficacy, emergence of viral mutations and the paucity of cell-tissue targeting remain. We posit that to maximize ART potency and therapeutic outcomes newer drug formulations that reach HIV cellular reservoirs need be created. In a step towards achieving this goal we harnessed the aggregation-induced emission (AIE) property of the non-nucleoside reverse transcriptase inhibitor rilpivirine (RPV) and used it as a platform for drug cell and subcellular tracking. RPV nanocrystals were created with endogenous AIE properties enabling the visualization of intracellular particles in cell and tissue-based assays. The intact drug crystals were easily detected in CD4

Indexed as

Anti-HIV AgentsHIV-1HIV InfectionsNanoparticlesDrug Resistance, ViralHumansReverse Transcriptase InhibitorsRilpivirineTissue DistributionAnti-HIV AgentsReverse Transcriptase InhibitorsRilpivirineAggregation-induced emissionAntiretroviral therapyCD4(+) T cell trackingDrug biodistributionMonocyte-macrophageRilpivirineSingle-crystal x-ray diffraction

Identifiers

PMID31865227
PMCPMC7334833

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.